Safety and Tolerability and Efficacy of LCZ696 in Japanese Severe Hypertensive Patients

Summary

This study assessed the safety, tolerability, and efficacy of LCZ696 in severe hypertensive Japanese patients

Timeline

Start

2012-07

Primary completion

2013-02

Completion

2013-02

Publications

• Results Kario K, Tamaki Y, Okino N, Gotou H, Zhu M, Zhang J. LCZ696, a First-in-Class Angiotensin Receptor-Neprilysin Inhibitor: The First Clinical Experience in Patients With Severe Hypertension. J Clin Hypertens (Greenwich). 2016 Apr;18(4):308-14. doi: 10.1111/jch.12667. Epub 2015 Sep 24.

Drugs

Indications